Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Wnt/β-catenin–activated Ewing sarcoma cells promote the angiogenic switch
Allegra G. Hawkins, Elisabeth A. Pedersen, Sydney Treichel, Kelsey Temprine, Colin Sperring, Jay A. Read, Brian Magnuson, Rashmi Chugh, Elizabeth R. Lawlor
Allegra G. Hawkins, Elisabeth A. Pedersen, Sydney Treichel, Kelsey Temprine, Colin Sperring, Jay A. Read, Brian Magnuson, Rashmi Chugh, Elizabeth R. Lawlor
View: Text | PDF
Research Article Cell biology Oncology

Wnt/β-catenin–activated Ewing sarcoma cells promote the angiogenic switch

  • Text
  • PDF
Abstract

Wnt/β-catenin signaling is active in small subpopulations of Ewing sarcoma cells, and these cells display a more metastatic phenotype, in part due to antagonism of EWS-FLI1–dependent transcriptional activity. Importantly, these β-catenin–activated Ewing sarcoma cells also alter secretion of extracellular matrix (ECM) proteins. We thus hypothesized that, in addition to cell-autonomous mechanisms, Wnt/β-catenin–active tumor cells might contribute to disease progression by altering the tumor microenvironment (TME). Analysis of transcriptomic data from primary patient biopsies and from β-catenin–active versus –nonactive tumor cells identified angiogenic switch genes as being highly and reproducibly upregulated in the context of β-catenin activation. In addition, in silico and in vitro analyses, along with chorioallantoic membrane assays, demonstrated that β-catenin–activated Ewing cells secreted factors that promote angiogenesis. In particular, activation of canonical Wnt signaling leads Ewing sarcoma cells to upregulate expression and secretion of proangiogenic ECM proteins, collectively termed the angiomatrix. Significantly, our data show that induction of the angiomatrix by Wnt-responsive tumor cells is indirect and is mediated by TGF-β. Mechanistically, Wnt/β-catenin signaling antagonizes EWS-FLI1–dependent repression of TGF-β receptor type 2, thereby sensitizing tumor cells to TGF-β ligands. Together, these findings suggest that Wnt/β-catenin–active tumor cells can contribute to Ewing sarcoma progression by promoting angiogenesis in the local TME.

Authors

Allegra G. Hawkins, Elisabeth A. Pedersen, Sydney Treichel, Kelsey Temprine, Colin Sperring, Jay A. Read, Brian Magnuson, Rashmi Chugh, Elizabeth R. Lawlor

×

Figure 6

Wnt/β-catenin sensitizes Ewing sarcoma cells to TGF-β pathway activation.

Options: View larger image (or click on image) Download as PowerPoint
Wnt/β-catenin sensitizes Ewing sarcoma cells to TGF-β pathway activation...
(A) qRT-PCR analysis of baseline TGFBR2 expression in Ewing sarcoma (A673, CHLA9, CHLA10, TC32), embryonic kidney cells (293FT cells purchased from ATCC) (negative control), and lung adenocarcinoma (A549) cell lines (positive control) (N = 3 replicates per cell line). (B) Measurement of TGFBR2 expression by qRT-PCR in Ewing sarcoma cells following knockdown of EWS-FLI1 (shFLI1). Expression is shown as fold change relative to cells transduced with nontargeting shRNA sequence (shNS). Results of replicate experiments are shown (N = 3, A673 and CHLA10; N = 2, TC32). P values were computed using 2-tailed t tests (A–C). *P < 0.05, **P < 0.005 (A and C). (C) qRT-PCR of TGFBR2 expression in Ewing sarcoma cell lines following exposure to vehicle or recombinant Wnt3a (N = 3). (D) Correlation between LEF1 and TGFBR2 expression in patient tumor biopsies. GSE63157: N= 46 tumors; GSE34620: N = 117 tumors. Correlation was computed using Pearson’s correlation, and P values were determined using 2-sided t tests. (E) Western blot analysis for phospho-SMAD2 (p-SMAD2) was performed on whole-cell lysates from CHLA10 and TC32 cells treated with control L cell (Ctrl) or Wnt3a CM (Wnt3a) ± TGFB1 for 1 hour. GAPDH served as the loading control and A549 as positive control for activated TGF-β signaling. Densitometry was used to calculate p-SMAD2 levels in each condition relative to Ctrl cells without TGFB1.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts